Description

Ticagrelor CAS NO 274693-27-5 is a potent and selective P2Y12 receptor antagonist, functioning as a direct-acting, reversibly-binding antiplatelet agent. Its primary commercial value lies in its critical role as the active pharmaceutical ingredient (API) in life-saving cardiovascular medications used to prevent thrombotic events. This high-purity compound is essential for pharmaceutical manufacturers and research institutions focused on developing and producing treatments for acute coronary syndrome (ACS) and other conditions requiring platelet inhibition.

Application

• Active Pharmaceutical Ingredient (API): Core component in the manufacture of finished oral solid dosage forms (tablets) for the prevention of atherothrombotic events.
• Cardiovascular Drug Formulation: Specifically used in medications for patients with Acute Coronary Syndrome (ACS) or a history of myocardial infarction (MI).
• Pharmaceutical Research & Development (R&D): Serves as a key reference standard and starting material for developing new antiplatelet therapies and combination drugs.
• Generic Drug Manufacturing: Critical for companies producing bioequivalent versions of originator antiplatelet drugs.
• Clinical Trial Material (CTM): Supplied under GMP conditions for use in Phase I-III clinical studies investigating new indications or formulations.
• Analytical Testing & Quality Control: Used as a certified reference standard in HPLC, LC-MS, and other analytical methods for assay and impurity profiling.

Basic Information

Product Name	Ticagrelor
CAS No.	274693-27-5
Molecular Formula	C23H28F2N6O4S
Molecular Weight	522.57 g/mol
Synonyms	(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; AZD6140; AR-C126532XX; Brillinta® (Trade Name API); Ticagrelorum; Ticagrelor API
EINECS	Contact for details

Quality Control

Our Ticagrelor is manufactured and tested under a strict quality management system. We provide material that meets or exceeds the specifications of major pharmacopoeias, including USP and EP monographs where applicable. Every batch is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles, ensuring reliable consistency and regulatory compliance for your pharmaceutical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a low-humidity environment to prevent degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.5%
Related Substances (HPLC)	Total impurities ≤1.5% Any single unknown impurity ≤0.10%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤20 ppm
Loss on Drying	≤0.5%
Specific Rotation	Contact for details

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.